Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation

被引:29
|
作者
Rayes, N
Seehofer, D
Hopf, U
Neuhaus, R
Naumann, U
Bechstein, WO
Neuhaus, P
机构
[1] Humboldt Univ, Dept Surg, D-13355 Berlin, Germany
[2] Humboldt Univ, Dept Internal Med, Charite Campus Virchow Clin, D-13355 Berlin, Germany
关键词
D O I
10.1097/00007890-200101150-00016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Preliminary results of short-term famciclovir and lamivudine therapy in patients with hepatitis B virus (HBV) infection after liver transplantation revealed promising results. In a retrospective study the efficacy of long-term treatment with these substances was compared. Methods. A total of 53 HBV-infected adults (48 reinfections and 7 de novo infections) received antiviral treatment. A total of 32 of these patients were treated with famciclovir 3x500 mg, 20 of them were later switched to lamivudine, Fourteen patients received lamivudine, 150 mg/day orally, as first line therapy and 7 patients after failure of famciclovir-prophylaxis. Follow-up time was 8 to 62 months (mean 35 months). Response to therapy (HBV-DNA negative) was compared using Kaplan-Meier estimates. Potential influence factors (HBV-DNA and HBeAg pretransplant, HDV coinfection, pretreatment with famciclovir and immunosuppression) on treatment response were analyzed by log. Rank test (univariate); then a multivariate analysis (Cox multiple stepwise regression model) was applied. Results. A total of 19 and 76% of the patients treated with famciclovir and lamivudine resp. became HBV-DNA negative; 0 and 24% HBsAg negative. Lamivudine was also effective as second Line therapy. In a multivariate analysis of all 73 treatment courses, lamivudine treatment and KDV-coinfection were significant factors for better treatment response; regarding only the lamivudine group, negative HBeAg pretransplant was significant. Viral breakthrough after prolonged treatment occurred in 55% (lamivudine) to 80% (famciclovir) of treatment courses but was only accompanied by mild hepatitis. Conclusions. Lamivudine and famciclovir are potent drugs for the treatment of HBV-infection after liver transplantation. The antiviral capacity of lamivudine is superior even after pretreatment with famciclovir but after prolonged treatment viral breakthrough is often observed.
引用
收藏
页码:96 / 101
页数:6
相关论文
共 50 条
  • [21] Long-term outcome of kidney transplantation in chronic hepatitis B carriers on lamivudine treatment
    Lau, S. C.
    Lai, W. M.
    Chiu, M. C.
    Tong, P. C.
    Tse, K. C.
    [J]. PEDIATRIC NEPHROLOGY, 2007, 22 (09) : 1584 - 1584
  • [22] Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation
    Tillmann, HL
    Trautwein, C
    Bock, T
    Glowenka, M
    Kruger, M
    Boker, K
    Jackel, E
    Pichlmayr, R
    Condreay, L
    Bruns, I
    Deslaurias, M
    Gauthier, J
    Manns, MP
    [J]. HEPATOLOGY, 1997, 26 (04) : 1202 - 1202
  • [23] Famciclovir treatment of chronic hepatitis B virus infection after kidney transplantation
    Tillmann, HL
    Kliem, V
    Eisenberger, U
    Petersen, R
    Dannenberg, B
    Koch, KM
    Pichlmayr, R
    Manns, MP
    Brunkhorst, R
    [J]. HEPATOLOGY, 1997, 26 (04) : 1948 - 1948
  • [24] Lamivudine for hepatitis B after liver transplantation
    Mutimer, D
    [J]. LIVER TRANSPLANTATION, 2001, 7 (06) : 511 - 512
  • [25] Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children.
    Shapira, R
    Mor, E
    Bar-Nathan, N
    Tur-Kaspa, R
    Dinari, G
    Ben-Ari, Z
    [J]. HEPATOLOGY, 2000, 32 (04) : 595A - 595A
  • [26] Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation
    Ferretti, G
    Merli, M
    Corradini, SG
    Callejon, V
    Tanzilli, P
    Masini, A
    Ferretti, S
    Iappelli, M
    Rossi, M
    Rivanera, D
    Lilli, D
    Mancini, C
    Attili, A
    Berloco, P
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (03) : 535 - 538
  • [27] Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation
    Yuefeng, M.
    Weili, F.
    Wenxiang, T.
    Ligang, X.
    Guiling, L.
    Hongwei, G.
    Wencai, L.
    Xiaoguang, W.
    Wei, M.
    Zhongyi, F.
    [J]. CLINICAL TRANSPLANTATION, 2011, 25 (04) : 517 - 522
  • [28] Famciclovir treatment of hepatitis B virus (HBV) infection after liver transplantation (OLT): A pilot study.
    Prieto, M
    Cordoba, J
    Berenguer, M
    Rayon, M
    Carrasco, D
    Olaso, V
    Mir, J
    Berenguer, J
    [J]. HEPATOLOGY, 1996, 24 (04) : 1169 - 1169
  • [29] Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation
    Panos, George Z.
    Lampropoulos, Konstantinos M.
    Angelousi, Anna G.
    Charatsis, Gerasimos G.
    Falagas, Matthew E.
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (02) : 222 - 223
  • [30] Long-term outcome of hepatitis C virus infection after liver transplantation
    Boker, KHW
    Dalley, G
    Bahr, MJ
    Maschek, H
    Tillmann, HL
    Trautwein, C
    Oldhaver, K
    Bode, U
    Pichlmayr, R
    Manns, MP
    [J]. HEPATOLOGY, 1997, 25 (01) : 203 - 210